查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1756476

基準標記市場，按產品、按方式、按癌症類型、按最終用戶、按國家和地區 - 行業分析、市場規模、市場佔有率及預測（2024 年至 2032 年）

Fiducial Marker Market, By Product, By Modality, By Cancer Type, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 399 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

2024 年基準標記市場規模價值為 1.689 億美元，2024 年至 2032 年的複合年成長率為 8.70%。

基準標記市場-市場動態

影像引導療法的採用率不斷提高

腫瘤科、神經科和心臟科擴大採用影像引導療法，這是基準標記市場發展的關鍵驅動力。這些手術高度依賴解剖目標的高精度定位，以提高治療準確性並減少併發症。基準標記作為可靠的參考點，在將影像資料與患者解剖結構對齊方面發揮著至關重要的作用，尤其是在立體定位放射外科或質子治療等複雜干預措施中。隨著醫療保健提供者越來越傾向於微創和標靶治療方案，對基準標記的需求激增。此外，包括MRI、CT和混合PET/CT系統在內的影像技術的進步，擴展了基準標記在各種臨床環境中的實用性。癌症和慢性病盛行率的上升進一步加劇了對精準治療計畫的需求，使得基準標記成為現代治療工作流程中的重要工具。預計這一趨勢將推動市場持續成長。

基準標記市場-關鍵見解

根據我們的研究分析師，全球基準標記市場預計在 2024 年至 2032 年期間的複合年成長率約為 8.70%。

按 2024 年的產品細分，金屬基標記物類別佔據了市場主導地位。

根據模式，超音波在 2024 年產生的收入最多。

按地區分類，2024年北美是收入最高的地區。

基準標記市場-細分分析：

全球基準標記市場分為四大類：產品、模式、癌症類型、最終用戶和地區。

基準標記市場按產品細分為金屬基標記、聚合物基標記和其他基準標記。其中，金屬基標記因其卓越的可視性以及與CT、MRI和X光等各種成像方式的兼容性，預計將佔據市場主導地位。這些標記通常由金、鉑或不銹鋼製成，具有高對比度和體內長期穩定性，使其成為需要重複成像的程序的理想選擇，例如放射治療計劃和影像引導手術。其耐用性和低遷移風險提高了程序的準確性，尤其是在腫瘤學應用中。金屬基基準點在臨床上的廣泛認可，以及其在改善治療效果方面的已證實的功效，進一步鞏固了其市場領導地位。隨著精準醫療和微創治療需求的持續成長，金屬基標記的強大性能和可靠性使其成為全球醫療保健系統的首選。

按癌症類型細分，基準標記市場包括攝護腺癌、肺癌、胃癌、乳癌和其他癌症。其中，前列腺癌佔最大佔有率，預計仍將佔據主導地位。這主要是因為基準標記在前列腺癌治療的影像導引放射治療 (IGRT) 和立體定位放射治療 (SBRT) 中廣泛使用。由於膀胱和直腸充盈，前列腺往往會輕微移位，因此準確定位至關重要。金屬基準標記，尤其是金標記，通常被植入前列腺，以確保每次治療期間的精確定位，從而改善治療效果並最大限度地減少對周圍組織的損傷。全球前列腺癌發生率的上升，以及人們對先進放射治療技術的認知和採用的不斷提高，正在推動該領域對基準標記的持續需求。臨床方案的加強和報銷支持進一步鞏固了其市場主導地位。

基準標記市場-地理洞察

從地理分佈來看，基準標記市場分佈於北美、亞太地區、拉丁美洲、歐洲、中東和非洲。這些區域根據業務開展的國家進一步分類。

北美在基準標記市場佔據主導地位，主要得益於其先進的醫療基礎設施、影像引導療法的高採用率以及對癌症治療技術的大量投資。美國尤其引領市場，因為其癌症（尤其是前列腺癌和肺癌）發生率高，這推動了對基準標記等精準診斷和治療工具的需求。此外，強大的報銷政策加上完善的醫療保健體系，促進了基準標記在放射治療和外科手術中的廣泛應用。此外，微創治療和影像技術的持續研究與創新也持續支撐著市場的成長。該地區的主導地位也得益於主要市場參與者的存在，這進一步推動了基準標記的應用和產品開發。

歐洲是另一個對基準標記市場貢獻巨大的關鍵地區。先進醫療技術的採用，加上對精準醫療和標靶癌症治療的日益重視，促進了該地區對基準標記的需求。德國、英國、法國和義大利等國家憑藉其高度發展的醫療體系和不斷上升的癌症發生率，引領市場。歐洲醫療保健機構擴大在影像導引放射治療中使用基準標記，尤其是在攝護腺癌、乳癌和肺癌治療中。該地區強大的監管框架以及對臨床研究和創新的支持，為基準標記使用量的成長鋪平了道路。此外，對微創治療的日益偏好以及對改善患者預後的日益關注，進一步推動了市場的發展。

基準標示市場-競爭格局：

基準標記市場的競爭態勢由許多老牌企業和專注於創新的新興公司共同塑造。 CIVCO Radiotherapy、波士頓科學公司、IZI Medical Products、美敦力和 IBA 等主要市場參與者佔據了相當大的市場佔有率，提供針對各種醫學成像應用量身定做的各種高品質基準標記。這些公司在研發方面投入巨資，以增強產品功能、提高精準度並確保合規性。 Nanovi A/S 和 Innovative Oncology Solutions 等新進業者正在推出先進技術，例如可視性更高、更易於植入的下一代基準標記。這種競爭格局推動了該領域的持續進步，創造了創新環境，最終提高了手術的準確性和有效性。例如，美敦力透過持續的研發和先進成像技術的開發，不斷在該領域進行創新，並保持了其在市場上的領先地位。

最新動態：

2023年10月，丹麥醫療器材公司Nanovi A/S（專注於液體基準標記）被CQ Medical（前身為CIVCO Radiotherapy和Qfix）收購。此次收購將Nanovi的創新BioXmark(R)技術整合到CQ Medical的產品組合中，增強其在高精度放射治療領域的產品組合。 BioXmark(R)是一種可生物分解的液體標記，具有出色的成像可視性，且偽影極少，適用於包括CT和MRI在內的各種成像方式。

2023 年 6 月，CIVCO Radiotherapy 收購了 Best Medical International, Inc.，擴大了其產品組合，進一步鞏固了其在基準標記市場的地位。

2022 年 2 月，波士頓科學公司推出了一種旨在增強 MRI 相容性的新型基準標記，可提高病患安全性和治療準確性。

目錄

第1章：基準標記市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 基準標示市場（按產品）片段
    • 基準標示市場片段（按模式）
    • 基準標記市場片段（按癌症類型）
    • 基準標記市場片段（按最終用戶）
    • 基準標記市場（按國家/地區）
    • 基準標示市場（按地區）
  • 競爭洞察

第3章：基準標示關鍵市場趨勢

  • 基準標記市場促進因素
    • 市場促進因素的影響分析
  • 基準標記市場限制
    • 市場限制的影響分析
  • 基準標記市場機會
  • 基準標記市場未來趨勢

第4章：基準標記產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：基準標記市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：基準標示市場格局

  • 2023年基準標示市佔率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：基準標示市場 - 按產品

  • 概述
    • 按產品細分的市佔率分析
    • 金屬基標記物
      • 純金標記
      • 金色組合標記
      • 其他金屬標記物
    • 聚合物標記物
    • 其他基準標記

第 8 章：基準標示市場 - 按模式

  • 概述
    • 按方式分類的細分市場佔有率分析
    • 掃描/輸血
    • 超音波
    • 磁振造影
    • 放射治療

第9章：基準標示市場－依癌症類型

  • 概述
    • 按癌症類型分析細分佔有率
    • 攝護腺癌
    • 肺癌
    • 胃癌
    • 乳癌
    • 其他癌症

第 10 章：基準標記市場 - 按最終用戶

  • 概述
    • 按最終用戶細分的佔有率分析
    • 醫院和門診設施
    • 獨立放射治療中心
    • 癌症研究中心

第 11 章：基準標示市場 - 按地理分類

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美基準標記主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模及預測（按產品）
    • 北美市場規模及預測（依方式）
    • 北美市場規模及預測（按癌症類型）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲基準標線主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模及預測（按產品）
    • 歐洲市場規模及預測（依方式）
    • 歐洲市場規模及預測（按癌症類型）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區基準標示主要製造商
    • 亞太市場規模及預測（按國家/地區）
    • 亞太市場規模及預測（按產品）
    • 亞太市場規模及預測（依方式）
    • 亞太市場規模及預測（按癌症類型）
    • 亞太市場規模及預測（依最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲基準標記關鍵製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（按產品）
    • 拉丁美洲市場規模及預測（按方式）
    • 拉丁美洲市場規模及預測（按癌症類型）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲的基準標記主要製造商
    • 中東和非洲市場規模及預測（按國家/地區）
    • 中東和非洲市場規模及預測（按產品）
    • 中東和非洲市場規模及預測（按方式）
    • 中東和非洲市場規模及預測（按癌症類型）
    • 中東和非洲市場規模及預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 12 章：關鍵供應商分析-基準標記產業

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • CIVCO Radiotherapy
    • Boston Scientific Corporation
    • IZI Medical Products
    • IBA
    • Naslund Medical AB
    • Medtronic
    • Best Medical International, Inc.
    • Nanovi A/S
    • Carbon Medical Technologies
    • Eckert & Ziegler
    • Innovative Oncology Solutions
    • QlRad Inc.
    • Stellar Medical
    • JJ-Medtech
    • QFIX
    • Others

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5293

REPORT HIGHLIGHT

Fiducial Marker Market size was valued at USD 168.9 Million in 2024, expanding at a CAGR of 8.70% from 2024 to 2032.

In healthcare, a fiducial marker is a reference point or object placed in or on the body to assist with precise localization during medical imaging, diagnostic procedures, or treatment planning. These markers are commonly used in radiology, radiation therapy, and surgical navigation to align imaging data with anatomical structures. Fiducial markers can be external (placed on the skin) or internal (implanted into tissues or tumors). Materials such as gold, carbon, or polymer are often used due to their visibility in imaging modalities like CT, MRI, and X-rays. In cancer treatment, for example, fiducial markers are implanted near tumors to help guide radiation beams with high accuracy, minimizing damage to healthy tissue. Similarly, in neurosurgery or robotic-assisted surgeries, fiducials provide reference points that enhance navigation systems. Their use significantly improves procedural precision, outcomes, and patient safety by ensuring accurate targeting and consistent positioning throughout treatment or surgical interventions.

Fiducial Marker Market- Market Dynamics

Increasing Adoption of Image-Guided Therapies

The growing adoption of image-guided therapies in oncology, neurology, and cardiology is a key driver for the fiducial markers market. These procedures rely heavily on high-precision localization of anatomical targets to enhance treatment accuracy and reduce complications. Fiducial markers play a crucial role by serving as reliable reference points for aligning imaging data with the patient's anatomy, especially in complex interventions such as stereotactic radiosurgery or proton therapy. As healthcare providers increasingly prefer minimally invasive and targeted treatment options, the demand for fiducials has surged. Moreover, advancements in imaging technologies, including MRI, CT, and hybrid PET/CT systems, have expanded the utility of fiducial markers across diverse clinical settings. The rising prevalence of cancer and chronic diseases further contributes to the need for accurate treatment planning, positioning fiducial markers as an essential tool in modern therapeutic workflows. This trend is expected to drive sustained market growth.

FIDUCIAL MARKER Market- Key Insights

According to our research analyst, the global Fiducial Marker Market is expected to develop at a CAGR of approximately 8.70% between 2024-2032.

Segmented by Product in 2024, the Metal-Based Markers category dominated the market.

Based on Modality, the Ultrasound generated the most income in 2024.

Based on region, in 2024, North America was the region with the highest revenue.

Fiducial Marker Market- Segmentation Analysis:

The global Fiducial Marker market is divided into four categories: Product, Modality, Cancer Type, End User and Region.

The fiducial markers market is segmented by product into Metal-Based Markers, Polymer-Based Markers, and Other Fiducial Markers. Among these, Metal-Based Markers are expected to dominate the market due to their superior visibility and compatibility with various imaging modalities such as CT, MRI, and X-ray. Typically made from gold, platinum, or stainless steel, these markers provide high contrast and long-term stability within the body, making them ideal for procedures requiring repeated imaging, such as radiotherapy planning and image-guided surgery. Their durability and low risk of migration enhance procedural accuracy, particularly in oncology applications. The widespread clinical acceptance of metal-based fiducials, along with their proven efficacy in improving treatment outcomes, further supports their market leadership. As the demand for precision medicine and minimally invasive treatments continues to grow, the robust performance and reliability of metal-based markers position them as the preferred choice across global healthcare systems.

The fiducial markers market, when segmented by cancer type, includes Prostate Cancer, Lung Cancer, Gastric Cancer, Breast Cancer, and Other Cancers. Among these, Prostate Cancer accounts for the largest share and is expected to remain the dominant segment. This is largely due to the widespread use of fiducial markers in image-guided radiation therapy (IGRT) and stereotactic body radiation therapy (SBRT) for prostate cancer treatment. The prostate gland tends to shift slightly due to bladder and rectal filling, making accurate localization critical. Metal-based fiducial markers, especially gold markers, are routinely implanted in the prostate to ensure precise targeting during each treatment session, improving outcomes while minimizing damage to surrounding tissues. The rising global incidence of prostate cancer, along with increased awareness and adoption of advanced radiotherapy techniques, is driving the sustained demand for fiducial markers in this segment. Enhanced clinical protocols and reimbursement support further contribute to its market dominance.

Fiducial Marker Market- Geographical Insights

Geographically, the Fiducial Marker Market is distributed throughout North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa. These regions are further divided based on the nations bringing in business.

North America holds a dominant position in the fiducial marker market, primarily driven by advanced healthcare infrastructure, high adoption rates of image-guided therapies, and significant investments in cancer treatment technologies. The United States, in particular, leads the market due to the high prevalence of cancer, especially prostate and lung cancer, which drives the demand for accurate diagnostic and therapeutic tools such as fiducial markers. Additionally, strong reimbursement policies, coupled with a well-established healthcare system, facilitate the widespread usage of fiducials in radiotherapy and surgical procedures. Furthermore, ongoing research and innovation in minimally invasive treatments and imaging technologies continue to support market growth. The region's dominance is also supported by the presence of key market players, further driving adoption and product development.

Europe is another key region contributing significantly to the fiducial marker market. The adoption of advanced healthcare technologies, coupled with a growing emphasis on precision medicine and targeted cancer therapies, has fostered the demand for fiducial markers in the region. Countries such as Germany, the UK, France, and Italy lead the market, owing to their highly developed healthcare systems and increasing cancer incidence rates. European healthcare providers are increasingly utilizing fiducial markers in image-guided radiation therapy, particularly for prostate, breast, and lung cancers. The region's strong regulatory frameworks, along with the support for clinical research and innovation, have paved the way for the growth of fiducial marker usage. Furthermore, the increasing preference for minimally invasive treatments and the growing focus on improving patient outcomes further boost the market.

Fiducial Marker Market- Competitive Landscape:

The competitive dynamics of the Fiducial Marker market are shaped by a mix of established players and emerging companies focused on innovation. Key market players such as CIVCO Radiotherapy, Boston Scientific Corporation, IZI Medical Products, Medtronic, and IBA hold significant market shares, offering a wide range of high-quality fiducial markers tailored for various medical imaging applications. These companies invest heavily in research and development to enhance product features, improve precision, and ensure regulatory compliance. New entrants, like Nanovi A/S and Innovative Oncology Solutions, are introducing advanced technologies such as next-gen fiducials with enhanced visibility and ease of implantation. This competitive landscape drives continuous advancements in the sector, fostering an environment of innovation that ultimately improves the accuracy and effectiveness of procedures. For instance, Medtronic continues to innovate in the field with its ongoing R&D and the development of advanced imaging technologies, maintaining its leadership in the market.

Recent Developments:

In October 2023, Nanovi A/S, a Danish medical device company specializing in liquid fiducial markers, was acquired by CQ Medical (formerly CIVCO Radiotherapy and Qfix). This acquisition integrates Nanovi's innovative BioXmark(R) technology into CQ Medical's portfolio, enhancing its offerings in high-precision radiation therapy. BioXmark(R) is a biodegradable liquid marker that provides excellent imaging visibility with minimal artifacts, making it suitable for various imaging modalities, including CT and MRI.

In June 2023, CIVCO Radiotherapy expanded its portfolio with the acquisition of Best Medical International, Inc., further strengthening its position in the fiducial marker market.

In February 2022, Boston Scientific Corporation launched a new fiducial marker designed for enhanced MRI compatibility, offering improved patient safety and treatment accuracy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL FIDUCIAL MARKER MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • CIVCO Radiotherapy
  • Boston Scientific Corporation
  • IZI Medical Products
  • IBA
  • Naslund Medical AB
  • Medtronic
  • Best Medical International, Inc.
  • Nanovi A/S
  • Carbon Medical Technologies
  • Eckert & Ziegler
  • Innovative Oncology Solutions
  • QlRad Inc.
  • Stellar Medical
  • JJ-Medtech
  • QFIX
  • Others

GLOBAL FIDUCIAL MARKER MARKET, BY PRODUCT- MARKET ANALYSIS, 2019 - 2032

  • Metal-Based Markers
  • Pure Gold Markers
  • Gold Combination Markers
  • Other Metal-Based Markers
  • Polymer-Based Markers
  • Other Fiducial Markers

GLOBAL FIDUCIAL MARKER MARKET, BY MODALITY - MARKET ANALYSIS, 2019 - 2032

  • CT/CBCT
  • Ultrasound
  • MRI
  • Radiotherapy

GLOBAL FIDUCIAL MARKER MARKET, BY CANCER TYPE - MARKET ANALYSIS, 2019 - 2032

  • Prostate Cancer
  • Lung Cancer
  • Gastric Cancer
  • Breast Cancer
  • Other Cancers

GLOBAL FIDUCIAL MARKER MARKET, BY END USER - MARKET ANALYSIS, 2019 - 2032

  • Hospitals & Outpatient Facilities
  • Independent Radiotherapy Centers
  • Cancer Research Centers

GLOBAL FIDUCIAL MARKER MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Fiducial Marker Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Fiducial Marker Market Snippet by Product
    • 2.1.2. Fiducial Marker Market Snippet by Modality
    • 2.1.3. Fiducial Marker Market Snippet by Cancer Type
    • 2.1.4. Fiducial Marker Market Snippet by End User
    • 2.1.5. Fiducial Marker Market Snippet by Country
    • 2.1.6. Fiducial Marker Market Snippet by Region
  • 2.2. Competitive Insights

3. Fiducial Marker Key Market Trends

  • 3.1. Fiducial Marker Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Fiducial Marker Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Fiducial Marker Market Opportunities
  • 3.4. Fiducial Marker Market Future Trends

4. Fiducial Marker Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Fiducial Marker Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Fiducial Marker Market Landscape

  • 6.1. Fiducial Marker Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Fiducial Marker Market - By Product

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product, 2023 & 2032 (%)
    • 7.1.2. Metal-Based Markers
      • 7.1.2.1. Pure Gold Markers
      • 7.1.2.2. Gold Combination Markers
      • 7.1.2.3. Other Metal-Based Markers
    • 7.1.3. Polymer-Based Markers
    • 7.1.4. Other Fiducial Markers

8. Fiducial Marker Market - By Modality

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Modality, 2023 & 2032 (%)
    • 8.1.2. Ct/Cbct
    • 8.1.3. Ultrasound
    • 8.1.4. MRI
    • 8.1.5. Radiotherapy

9. Fiducial Marker Market - By Cancer Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Cancer Type, 2023 & 2032 (%)
    • 9.1.2. Prostate Cancer
    • 9.1.3. Lung Cancer
    • 9.1.4. Gastric Cancer
    • 9.1.5. Breast Cancer
    • 9.1.6. Other Cancers

10. Fiducial Marker Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 10.1.2. Hospitals & Outpatient Facilities
    • 10.1.3. Independent Radiotherapy Centers
    • 10.1.4. Cancer Research Centers

11. Fiducial Marker Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Fiducial Marker Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Fiducial Marker Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Fiducial Marker Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Fiducial Marker Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Fiducial Marker Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Fiducial Marker Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. CIVCO Radiotherapy
    • 12.2.2. Boston Scientific Corporation
    • 12.2.3. IZI Medical Products
    • 12.2.4. IBA
    • 12.2.5. Naslund Medical AB
    • 12.2.6. Medtronic
    • 12.2.7. Best Medical International, Inc.
    • 12.2.8. Nanovi A/S
    • 12.2.9. Carbon Medical Technologies
    • 12.2.10. Eckert & Ziegler
    • 12.2.11. Innovative Oncology Solutions
    • 12.2.12. QlRad Inc.
    • 12.2.13. Stellar Medical
    • 12.2.14. JJ-Medtech
    • 12.2.15. QFIX
    • 12.2.16. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us